Health Care [ 5/12 ] | Health Care Equipment & Supplies [ 38/73 ]
NASDAQ | Common Stock
biote Corp. operates in practice-building business within the hormone optimization space.
It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance.
The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.
It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female.
The company was founded in 2012 and is headquartered in Irving, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 6, 25 | 0.10 Increased by +166.67% | 0.08 Increased by +25.00% |
| May 9, 25 | 0.37 Increased by +716.67% | 0.14 Increased by +164.29% |
| Mar 12, 25 | 0.10 Decreased by -44.44% | 0.11 Decreased by -9.09% |
| Nov 12, 24 | 0.33 Increased by +37.50% | 0.12 Increased by +175.00% |
| Aug 8, 24 | -0.15 Increased by +40.00% | 0.09 Decreased by -266.67% |
| May 7, 24 | -0.06 Increased by +84.62% | 0.03 Decreased by -300.00% |
| Mar 12, 24 | 0.18 Increased by 0.00% | 0.08 Increased by +125.00% |
| Nov 7, 23 | 0.24 Increased by +113.79% | 0.08 Increased by +200.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 48.86 M Decreased by -0.62% | 3.19 M Increased by +150.38% | Increased by +6.52% Increased by +150.70% |
| Mar 31, 25 | 48.99 M Increased by +4.67% | 13.72 M Increased by +762.71% | Increased by +28.00% Increased by +733.11% |
| Dec 31, 24 | 49.83 M Increased by +9.04% | 3.70 M Decreased by -52.12% | Increased by +7.43% Decreased by -56.09% |
| Sep 30, 24 | 51.38 M Increased by +12.79% | 10.70 M Increased by +42.12% | Increased by +20.83% Increased by +26.01% |
| Jun 30, 24 | 49.17 M Decreased by -0.18% | -6.32 M Decreased by -22.92% | Decreased by -12.86% Decreased by -23.14% |
| Mar 31, 24 | 46.80 M Increased by +4.37% | -2.07 M Increased by +69.58% | Decreased by -4.42% Increased by +70.86% |
| Dec 31, 23 | 45.70 M Increased by +2.74% | 7.73 M Decreased by -39.62% | Increased by +16.92% Decreased by -41.23% |
| Sep 30, 23 | 45.56 M Increased by +8.55% | 7.53 M Increased by +218.66% | Increased by +16.53% Increased by +209.31% |